US 12,364,699 B2
Method of treating hair loss disorders
Christopher L. Brummel, Lexington, MA (US); James V. Cassella, Lexington, MA (US); and Meghan A. Holden, Lexington, MA (US)
Assigned to Sun Pharmaceuticals Industries, Inc., Princeton, NJ (US)
Filed by Sun Pharmaceutical Industries, Inc., Princeton, NJ (US)
Filed on Oct. 3, 2024, as Appl. No. 18/905,898.
Claims priority of provisional application 63/697,634, filed on Sep. 23, 2024.
Claims priority of provisional application 63/675,577, filed on Jul. 25, 2024.
Claims priority of provisional application 63/673,600, filed on Jul. 19, 2024.
Claims priority of provisional application 63/625,125, filed on Jan. 25, 2024.
Claims priority of provisional application 63/543,885, filed on Oct. 12, 2023.
Claims priority of provisional application 63/543,470, filed on Oct. 10, 2023.
Prior Publication US 2025/0114366 A1, Apr. 10, 2025
Int. Cl. A61K 31/519 (2006.01); A61K 9/00 (2006.01); A61P 17/14 (2006.01)
CPC A61K 31/519 (2013.01) [A61K 9/0053 (2013.01); A61P 17/14 (2018.01)] 30 Claims
 
1. A method of treating alopecia areata in a subject in need thereof, the method comprising, orally administering to the subject 16 mg/day or 24 mg/day of Compound (I) or a pharmaceutically acceptable salt thereof, wherein Compound (I) is represented by the following structural formula:

OG Complex Work Unit Chemistry
wherein each position designated specifically as deuterium has at least 95% incorporation of deuterium, and
wherein the subject has an estimated glomerular filtration rate (eGFR) of ≥30 mL/min, MDRD.